Jul. 1 at 4:19 AM
$SLS incredible work being done but I'd like to highlight the potential for a partnership with cutting edge, genomic sequencing industry leader
$BNGO.
The REGAL trial, specifically the AML, is heavily dependent on genomic sequencing, structural variants karyotyping often misses.
$BNGO's Saphyr optical genome mapping could theoretically complement that kind of research.
